<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35217371</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-8615</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>69</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of critical care</Title>
          <ISOAbbreviation>J Crit Care</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Letter to the Editor: "Use of inhaled epoprostenol with high flow nasal oxygen in non-intubated patients with severe COVID-19".</ArticleTitle>
        <Pagination>
          <StartPage>153989</StartPage>
          <MedlinePgn>153989</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2022.153989</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0883-9441(22)00007-7</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Acute lung injury associated with COVID-19 contributes significantly to its morbidity and mortality. Though invasive mechanical ventilation is sometimes necessary, the use of high flow nasal oxygen may avoid the need for mechanical ventilation in some patients. For patients approaching the limits of high flow nasal oxygen support, addition of inhaled pulmonary vasodilators is becoming more common but little is known about its effects. This is the first descriptive study of a cohort of patients receiving inhaled epoprostenol with high flow nasal oxygen for COVID-19.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We collected clinical data from the first fifty patients to receive inhaled epoprostenol while on high flow nasal oxygen at our institution. We compared the characteristics of patients who did and did not respond to epoprostenol addition.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 18 patients that did not stabilize or improve following initiation of inhaled epoprostenol had similar rates of invasive mechanical ventilation as those who improved or stabilized (50% vs 56%). Rates of mortality were not significantly different between the two groups (17% and 31%).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with COVID-19 induced hypoxemic respiratory failure, the use of inhaled epoprostenol with high flow nasal oxygen is feasible, but physiologic signs of response were not related to clinical outcomes.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chiles</LastName>
            <ForeName>Joe W</ForeName>
            <Initials>JW</Initials>
            <Suffix>3rd</Suffix>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address: jwchiles@uabmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vijaykumar</LastName>
            <ForeName>Kadambari</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darby</LastName>
            <ForeName>Adrienne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goetz</LastName>
            <ForeName>Ryan L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kane</LastName>
            <ForeName>Lauren E</ForeName>
            <Initials>LE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Methukupally</LastName>
            <ForeName>Abhishek R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gandotra</LastName>
            <ForeName>Sheetal</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Russell</LastName>
            <ForeName>Derek W</ForeName>
            <Initials>DW</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whitson</LastName>
            <ForeName>Micah R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kelmenson</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary, Allergy &amp; Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Crit Care</MedlineTA>
        <NlmUniqueID>8610642</NlmUniqueID>
        <ISSNLinking>0883-9441</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>DCR9Z582X0</RegistryNumber>
          <NameOfSubstance UI="D011464">Epoprostenol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072601" MajorTopicYN="N">Cannula</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011464" MajorTopicYN="N">Epoprostenol</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063087" MajorTopicYN="Y">Noninvasive Ventilation</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Epoprostenol</Keyword>
        <Keyword MajorTopicYN="N">High-flow nasal cannula</Keyword>
        <Keyword MajorTopicYN="N">Hypoxemic respiratory failure</Keyword>
        <Keyword MajorTopicYN="N">Non-invasive positive pressure ventilation</Keyword>
        <Keyword MajorTopicYN="N">Pulmonary vasodilator</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest All authors have no competing interests to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35217371</ArticleId>
        <ArticleId IdType="pmc">PMC8863404</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jcrc.2022.153989</ArticleId>
        <ArticleId IdType="pii">S0883-9441(22)00007-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533â534. doi: 10.1016/S1473-3099(20)30120-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId>
            <ArticleId IdType="pmc">PMC7159018</ArticleId>
            <ArticleId IdType="pubmed">32087114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tzotzos S.J., Fischer B., Fischer H., Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516. doi: 10.1186/s13054-020-03240-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13054-020-03240-7</ArticleId>
            <ArticleId IdType="pmc">PMC7441837</ArticleId>
            <ArticleId IdType="pubmed">32825837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demoule A., Vieillard Baron A., Darmon M., Beurton A., Geri G., Voiriot G., et al.  High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020;202(7):1039â1042. doi: 10.1164/rccm.202005-2007LE.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.202005-2007LE</ArticleId>
            <ArticleId IdType="pmc">PMC7528777</ArticleId>
            <ArticleId IdType="pubmed">32758000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calligaro G.L., Lalla U., Audley G., Gina P., Miller M.G., Mendelson M., et al.  The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study. EClinicalMedicine. 2020;28 doi: 10.1016/j.eclinm.2020.100570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eclinm.2020.100570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borczuk A.C., Salvatore S.P., Seshan S.V., Patel S.S., Bussel J.B., Mostyka M., et al.  COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156â2168. doi: 10.1038/s41379-020-00661-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41379-020-00661-1</ArticleId>
            <ArticleId IdType="pmc">PMC7463226</ArticleId>
            <ArticleId IdType="pubmed">32879413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonti R., Pike C.W., Cobb N. Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19. J Intensive Care Med. 2021;36(3):327â333. doi: 10.1177/0885066620976525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0885066620976525</ArticleId>
            <ArticleId IdType="pmc">PMC7724253</ArticleId>
            <ArticleId IdType="pubmed">33234007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Fink J.B., Augustynovich A.E., Mirza S., Kallet R.H., Dhand R. Effects of inhaled epoprostenol and prone positioning in intubated coronavirus disease 2019 patients with refractory hypoxemia. Crit Care Explor. 2020;2(12) doi: 10.1097/CCE.0000000000000307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCE.0000000000000307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeGrado J.R., Szumita P.M., Schuler B.R., Dube K.M., Lenox J., Kim E.Y., et al.  Evaluation of the efficacy and safety of inhaled epoprostenol and inhaled nitric oxide for refractory hypoxemia in patients with coronavirus disease 2019. Crit Care Explor. 2020;2(10) doi: 10.1097/CCE.0000000000000259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCE.0000000000000259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esserman L.  Personal Communication; 2021. Personal communication.</Citation>
        </Reference>
        <Reference>
          <Citation>Chosidow S., Plantefeve G., Fraisse M., Mentec H., Cally R., Contou D. Non-intubated COVID-19 patients despite high levels of supplemental oxygen. Crit Care. 2021;25(1):170. doi: 10.1186/s13054-021-03599-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13054-021-03599-1</ArticleId>
            <ArticleId IdType="pmc">PMC8127232</ArticleId>
            <ArticleId IdType="pubmed">34001221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Harnois L.J., Markos B., Roberts K.M., Homoud S.A., Liu J., et al.  Epoprostenol delivered via high flow nasal cannula for ICU subjects with severe hypoxemia comorbid with pulmonary hypertension or right heart dysfunction. Pharmaceutics. 2019;11(6) doi: 10.3390/pharmaceutics11060281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pharmaceutics11060281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammar M.A., Sasidhar M., Lam S.W. Inhaled epoprostenol through noninvasive routes of ventilator support systems. Ann Pharmacother. 2018;52(12):1173â1181. doi: 10.1177/1060028018782209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028018782209</ArticleId>
            <ArticleId IdType="pubmed">29890848</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
